{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:45:38Z","timestamp":1792219538455,"version":"4.4.0"},"reference-count":67,"publisher":"Tech Science Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2024.054537","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T21:36:36Z","timestamp":1733952996000},"page":"919-935","source":"Crossref","is-referenced-by-count":4,"title":["ERLNs augment simultaneous delivery of GFSV into PC-3 cells: Influence of drug combination on SDH, GPX-4, 5\u03b1-RD, and cytotoxicity"],"prefix":"10.32604","volume":"33","author":[{"given":"RIYAD F.","family":"ALZHRANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAMA","family":"BINOBAID","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABDULAZIZ A.","family":"ALORAINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MESHAL S.","family":"ALSAHLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AHMED H.","family":"BAKHEIT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANADI H.","family":"ASIRI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SABRY M.","family":"ATTIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALI","family":"ALHOSHANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GAMALELDIN I.","family":"HARISA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Public Health Front"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/curroncol30020178","article-title":"Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis","volume":"30","author":"Berenguer","year":"2023","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.prnil.2016.05.002","article-title":"Oxidative stress in prostate cancer patients: a systematic review of case-control studies","volume":"4","author":"Oh","year":"2016","journal-title":"Prostate Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.18632\/oncotarget.14049","article-title":"Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors","volume":"8","author":"Feng","year":"2016","journal-title":"Oncotarget"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"17588359231152839","DOI":"10.1177\/17588359231152839","article-title":"Targeting lipid metabolism in metastatic prostate cancer","volume":"15","author":"Scheinberg","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41391-022-00554-1","article-title":"Statins and prostate cancer\u2014hype or hope? The epidemiological perspective","volume":"25","author":"Craig","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4251\/wjgo.v14.i1.110","article-title":"Statin as a therapeutic agent in gastroenterological cancer","volume":"14","author":"Uemura","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/ph15020131","article-title":"The effects of statins on prostate cancer patients receiving androgen deprivation therapy or definitive therapy: a systematic review and meta-analysis","volume":"15","author":"Hou","year":"2022","journal-title":"Pharmaceuticals"},{"key":"ref12","first-page":"e2078","article-title":"Statins as anti-tumor agents: a paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-023-02890-1","article-title":"Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations","volume":"23","author":"Ahmadi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jsps.2020.11.012","article-title":"Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability","volume":"28","author":"Faris","year":"2020","journal-title":"Saudi Pharm J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/pharmaceutics16030297","article-title":"Emerging trends of nanomedicines in the management of prostate cancer: perspectives and potential applications","volume":"16","author":"Deshmukh","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/10717544.2019.1588424","article-title":"Application and design of esterase-responsive nanoparticles for cancer therapy","volume":"26","author":"Dong","year":"2019","journal-title":"Drug Deliv"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","article-title":"Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery","volume":"18","author":"Majumder","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.3390\/app11209541","article-title":"Stimuli-responsive polymeric nanosystems for controlled drug delivery","volume":"11","author":"Xiang","year":"2021","journal-title":"Appl Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An overview of nanostructured lipid carriers and its application in drug delivery through different routes","volume":"13","author":"Khan","year":"2023","journal-title":"Adv Pharm Bull"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/pharmaceutics15030831","article-title":"Solid lipid nanoparticles: multitasking nano-carriers for cancer treatment","volume":"15","author":"German-Cort\u00e9s","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acsbiomaterials.1c01274","article-title":"Nanotechnology-based approaches to promote lymph node targeted delivery of cancer vaccines","volume":"8","author":"He","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1039\/C4NR04249B","article-title":"Enzyme-responsive nanomaterials for controlled drug delivery","volume":"6","author":"Hu","year":"2014","journal-title":"Nanoscale"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10717544.2020.1760962","article-title":"DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment","volume":"27","author":"Li","year":"2020","journal-title":"Drug Deliv"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7959","DOI":"10.2147\/IJN.S331060","article-title":"Prostate-specific membrane antigen and esterase dual responsive camptothecin-oligopeptide self-assembled nanoparticles for efficient anticancer drug delivery","volume":"16","author":"Xu","year":"2021","journal-title":"Int J Nanomed"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.jddst.2021.102409","article-title":"Chitosan coated solid lipid nanoparticles as promising carriers for docetaxel","volume":"62","author":"Dawoud","year":"2021","journal-title":"J Drug Deliv Technol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carbpol.2014.12.084","article-title":"Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake","volume":"122","author":"Luo","year":"2015","journal-title":"Carbohydr Polym"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"105414","DOI":"10.1016\/j.jddst.2024.105414","article-title":"Chitosan coated lipid carriers as nanoplatform for repurposed anti-breast cancer activity of niclosamide","volume":"93","author":"Elkholy","year":"2024","journal-title":"J Drug Deliv Technol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"111331","DOI":"10.1016\/j.colsurfb.2020.111331","article-title":"Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy","volume":"196","author":"Pyo","year":"2020","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/ijms24032914","article-title":"Optimization of the hemolysis assay for the assessment of cytotoxicity","volume":"24","author":"S\u00e6b\u00f8","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ddr.22097","article-title":"Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: codelivery and repurposing approach","volume":"84","author":"Sherif","year":"2023","journal-title":"Drug Dev Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J Comput Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cryst13071020","article-title":"Exploring the chemical reactivity, molecular docking, molecular dynamic simulation and ADMET properties of a tetrahydrothienopyridine derivative using computational methods","volume":"13","author":"Bakheit","year":"2023","journal-title":"Crystals"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1021\/cr300314q","article-title":"Integrated approach to structure-based enzymatic drug design: molecular modeling, spectroscopy, and experimental bioactivity","volume":"114","author":"Honarparvar","year":"2014","journal-title":"Chem Rev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","article-title":"Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges","volume":"36","author":"Gasteiger","year":"1980","journal-title":"Tetrahedron"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-2836(02)01036-7","article-title":"Analysis of catalytic residues in enzyme active sites","volume":"324","author":"Bartlett","year":"2002","journal-title":"J Mol Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s11033-024-09757-2","article-title":"Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities","volume":"51","author":"Harisa","year":"2024","journal-title":"Mol Biol Rep"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3390\/math10152549","article-title":"Application of intercriteria analysis to assess the performance of scoring functions in molecular docking software packages","volume":"10","author":"Jereva","year":"2022","journal-title":"Mathematics"},{"key":"ref39","first-page":"241","article-title":"PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: a combination therapy for prostate cancer using a drug repurposing strategy","volume":"13","author":"Yousefnezhad","year":"2023","journal-title":"BioImpacts"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1111\/jcmm.17286","article-title":"Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes","volume":"26","author":"Mirzaei","year":"2022","journal-title":"J Cell Mol Med"},{"key":"ref41","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Khan","year":"2013","journal-title":"Int J Nanomed"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"114614","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res Lett"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/B978-0-323-52725-5.00005-8","author":"Gumustas","year":"2017","journal-title":"Multifunctional systems for combined delivery, biosensing and diagnostics"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"122014","DOI":"10.1016\/j.ijpharm.2022.122014","article-title":"Design of nanostructured lipid carriers and solid lipid nanoparticles for enhanced cellular uptake","volume":"624","author":"Veider","year":"2022","journal-title":"Int J Pharm"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-022-01309-9","article-title":"Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances","volume":"20","author":"Mahmoud","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"109305","DOI":"10.1016\/j.cbi.2020.109305","article-title":"Erythrocytes as model cells for biocompatibility assessment, cytotoxicity screening of xenobiotics and drug delivery","volume":"332","author":"Podsiedlik","year":"2020","journal-title":"Chem Biol Interact"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/molecules21121641","volume":"21","author":"Guan","year":"2016","journal-title":"Molecules"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.actatropica.2019.01.008","volume":"192","author":"Oyama","year":"2019","journal-title":"Acta Trop"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/life12111890","article-title":"Suppression of SREBP-1 expression by simvastatin decreases visfatin-induced chemoresistance to sunitinib in human renal carcinoma 786-O cells","volume":"12","author":"Chen","year":"2022","journal-title":"Life"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/ph14050470","article-title":"Statin as a potential chemotherapeutic agent: current updates as a monotherapy, combination therapy, and treatment for anti-cancer drug resistance","volume":"14","author":"Tilija Pun","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/nano9030474","article-title":"Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs","volume":"9","author":"Bay\u00f3n-Cordero","year":"2019","journal-title":"Nanomater"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e20201850","DOI":"10.1590\/0001-3765202120201850","article-title":"The effect of chitosan addition on cellular uptake and cytotoxicity of ursolic acid niosomes","volume":"93","author":"Miatmoko","year":"2021","journal-title":"An Acad Bras Ci\u00eanc"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2006.08.029","volume":"43","author":"Qi","year":"2007","journal-title":"Eur J Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"928821","DOI":"10.3389\/fphar.2023.928821","article-title":"The role of cholesterol metabolism in tumor therapy, from bench to bed","volume":"14","author":"Xia","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.3390\/cancers15153948","article-title":"Statins in cancer prevention and therapy","volume":"15","author":"Ricco","year":"2023","journal-title":"Cancers"},{"key":"ref57","first-page":"1103","article-title":"Cholesterol metabolism in drug-resistant cancer","volume":"57","author":"Yan","year":"2020","journal-title":"Int J Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1007\/s11033-019-04958-6","article-title":"Cell signaling and cancer: a mechanistic insight into drug resistance","volume":"46","author":"Panda","year":"2019","journal-title":"Mol Biol Rep"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1188926","DOI":"10.3389\/fphar.2023.1188926","article-title":"New insights into the therapeutic potentials of statins in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3390\/ph16111549","article-title":"Development of gefitinib-loaded solid lipid nanoparticles for the treatment of breast cancer: physicochemical evaluation, stability, and anticancer activity in breast cancer (MCF-7) cells","volume":"16","author":"Aljuffali","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1039\/D3BM01735D","article-title":"Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression","volume":"12","author":"Xiong","year":"2024","journal-title":"Biomater Sci"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10787-018-0469-x","article-title":"Oxidative stress as a possible mechanism of statin-induced myopathy","volume":"26","author":"Ahmadi","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/medicina60020244","article-title":"The current and emerging role of statins in the treatment of PCOS: the evidence to date","volume":"60","author":"Kolnikaj","year":"2024","journal-title":"Medicina"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41416-019-0451-4","article-title":"Lipid metabolism in cancer cells under metabolic stress","volume":"120","author":"Munir","year":"2019","journal-title":"Br J Cancer"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4251\/wjgo.v15.i4.617","article-title":"Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy","volume":"15","author":"Feng","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"104104","DOI":"10.1016\/j.jddst.2022.104104","article-title":"Simvastatin-loaded PCL\/PEG nanofibrous scaffold: a prospective approach for suppression 5-fluorouracil resistance in MKN-45 gastric cancer cells","volume":"80","author":"Dolatabadi","year":"2023","journal-title":"J Drug Deliv Technol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/ph16111618","article-title":"Esterase-responsive polyglycerol-based nanogels for intracellular drug delivery in rare gastrointestinal stromal tumors","volume":"16","author":"Sch\u00f6tz","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-4\/OncolRes-33-04-54537\/OncolRes-33-54537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:32:30Z","timestamp":1763101950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n4\/60030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.054537","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}